Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy

Atherosclerosis. 2012 Mar;221(1):160-8. doi: 10.1016/j.atherosclerosis.2011.12.027. Epub 2012 Jan 4.

Abstract

Objective: To evaluate the impact of CETP inhibition on the capacity of individual postprandial HDL subspecies to promote key steps of the reverse cholesterol transport pathway.

Methods: The capacity of HDL particles to mediate cellular free cholesterol efflux and selective hepatic uptake of cholesteryl esters was evaluated throughout postprandial phase (0-8 h) following consumption of a standardised mixed meal before and after treatment for 6 weeks with atorvastatin alone (10 mg/d) and subsequently with combination torcetrapib/atorvastatin (60/10 mg/d) in 16 patients displaying low HDL-C levels (<40 mg/dl).

Results: The larger HDL2b and HDL2a subfraction displayed a superior capacity to mediate cellular free cholesterol efflux via both SR-BI and ABCG1-dependent pathways than smaller HDL3 subspecies. CETP inhibition specifically enhanced the capacity of HDL2b subfraction for both SR-BI and ABCG1 dependent efflux. However, only the SR-BI-dependent efflux to HDL2b subspecies can be further enhanced during postprandial lipemia following CETP inhibition. Concomitantly, postprandial lipemia was associated with a reduced capacity of total HDL particles to deliver cholesteryl esters to hepatic cells in a drug independent manner.

Conclusion: CETP inhibition specifically improves postprandial SR-BI and ABCG1-dependent efflux to larger HDL2b subspecies. In addition, CETP inhibition improves HDL-CE delivery to hepatic cells and maintains an efficient direct return of cholesteryl esters to the liver during postprandial lipemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily G, Member 1
  • ATP-Binding Cassette Transporters / genetics
  • ATP-Binding Cassette Transporters / metabolism
  • Adult
  • Animals
  • Apolipoprotein A-I / blood
  • Apolipoprotein A-II / blood
  • Atorvastatin
  • CD36 Antigens / metabolism
  • CHO Cells
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol Ester Transfer Proteins / metabolism
  • Cholesterol Esters / blood
  • Cholesterol, HDL / blood*
  • Cricetinae
  • Cricetulus
  • Drug Therapy, Combination
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Hypolipidemic Agents / therapeutic use*
  • Lipoproteins, HDL2 / blood*
  • Liver / drug effects
  • Liver / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Male
  • Mice
  • Middle Aged
  • Paris
  • Particle Size
  • Postprandial Period*
  • Pyrroles / therapeutic use*
  • Quinolines / therapeutic use*
  • Time Factors
  • Transfection
  • Treatment Outcome

Substances

  • ABCG1 protein, human
  • APOA1 protein, human
  • APOA2 protein, human
  • ATP Binding Cassette Transporter, Subfamily G, Member 1
  • ATP-Binding Cassette Transporters
  • Apolipoprotein A-I
  • Apolipoprotein A-II
  • CD36 Antigens
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol Esters
  • Cholesterol, HDL
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Lipoproteins, HDL2
  • Pyrroles
  • Quinolines
  • torcetrapib
  • Atorvastatin